Australia: Patent Term Extensions (PTEs) in Australia: under pressure - but safe for now

Last Updated: 8 September 2017
Article by Jacinta Flattery-O'Brien

Government responds to the Productivity Commission Report and the Courts find "Swiss-style" claims not sufficient for a PTE

The Australian Government, in its highly anticipated response to the Productivity Commission's Report, recommended only a minor change to the legislation relating to patent term extensions (PTEs). Almost simultaneously, in the equally eagerly-awaited decision of the Federal Court in Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129, it was found that Swiss-style claims do not confer eligibility for a PTE.

Some context: pressure on the PBS budget

Pharmaceuticals are subsidised in Australia by the taxpayer-funded Pharmaceutical Benefits Scheme (PBS). With a population of about 24 million, the Government is under severe and sustained pressure to reduce PBS expenditure from its current level of $10bn, but it must do so in difficult circumstances: the average life-span of Australians is increasing as is the consumption of drugs, while the retirement age is not due to be lifted for some time.

Vertex, for example, appears to have recently borne the brunt of this downward pressure in a spectacular failure to reach agreement with the Pharmaceutical Benefits Advisory Committee (PBAC), the body that recommends new medicines for listing on the PBS. In a controversial decision, for the third time the PBAC refused to list Vertex' combination cystic fibrosis drug Orkambi (lumacaftor/ivacaftor; understood to have been offered at around $300,000 per patient per year) because, as reported by Vertex' General Manager Simon Bedson, the company would not agree to the PBAC request for a 90% discount on the price tag. Bedson has called on Greg Hunt, the Minister of Health and the person responsible for PBS expenditure, to step in and to over-rule the PBAC.

Tough price negotiations on individual items aside, however, it is clear that containing the PBS budget requires heavy reliance on entry of "cheap" generic products into the market, not least because an automatic reduction of 16% applies to the innovator company's product once a generic drug is listed on the PBS. The need to contain costs, however, has to be balanced with allowing pharmaceutical companies to reap the benefits of the many years of research and testing required to bring a new product to market.

A tension arises, therefore, when the Patent Office, an instrument of Government, grants a PTE to compensate a patentee for time required to test and obtain regulatory approval for a drug covered by the patent, because the result is that the "high" price to the PBS is maintained for longer.

Government response to Productivity Commission recommendations in relation to PTE provisions

s70 Criteria for obtaining a PTE – Government rejects PC's suggested restrictions

Under s70 of the Australian Patents Act 1990, a patent can be extended for five years beyond the standard 20-year term. A PTE is available for patents covering new active pharmaceutical ingredients, new formulations of known active pharmaceutical ingredients and new methods of producing known pharmaceuticals when the methods involve the use of recombinant DNA technology. In order to be eligible, more than five years must have elapsed between the filing date of the patent and the date on which regulatory approval for a product covered by the patent was obtained in Australia.

The Australian Productivity Commission Inquiry Report (PC Report), published in December 2016, recommended that PTE legislation be reformed such that extensions are only:

  1. available for patents covering an active pharmaceutical ingredient, and
  2. calculated based on the time taken by the Australian regulatory approval body to approve the drug over and above 255 working days (one year).

Many thought that this recommendation was likely to be approved by the Government and that PTEs may even be phased out completely over time – remaining unpersuaded by the argument that abolishing the system was not a "genuine" option as it would be contrary to our obligations under international agreements.

In its Response to the PC Report, published on 25 August 2017, the Government noted the Commission's finding that "extensions of patent term prolong market exclusivity and impose significant costs on consumers, Government and taxpayers. The Commission estimated that the cost to the Government (through additional costs to the Pharmaceutical Benefits Scheme) of providing extensions of patent term to pharmaceuticals is approximately $260 million per annum." and further acknowledged that "the effective patent life of extended Australian patents is 12 months longer at the median than those in the United States and the average expiry date of extended Australian patents is 18 months later than those in the United States".

It will come as a relief to innovators to note that, notwithstanding those comments, the Government indicated that it has "no plans to proceed with the recommendation in the form proposed by the Productivity Commission. The Government will discuss ways to improve the patent term extension system with the sector."

For the foreseeable future, therefore, innovators will continue to enjoy up to five years' additional protection beyond the 20-year term of their Australian pharmaceutical patent.

S76A Financial report by PTE recipients

Beneficiaries of PTEs will also be pleased to note that the Government will consider repealing s76A of the Patents Act 1990. This section of the Act is poorly worded and ambiguous in its intent. It relates to an obligation on the patentee to provide a financial report to the Government concerning the use of Government funds by organisations involved in the development of the relevant pharmaceutical product. However, due to its deficiencies, it was difficult for patentees to be certain of the requirements and attempts at compliance could, depending on the interpretation of the statute and the circumstances, be very onerous.

Notwithstanding the lack of any apparent penalty for non-compliance, through abundance of caution, Shelston IP's advice to PTE recipients has always been to comply or at least to make an effort to comply with the requirements as we interpreted them. However, we understand that some patentees may have chosen to ignore the s76A requirements.

The PC Report recommended that the Australian Government "reform s76A of the Patents Act 1990 (Cth) to improve data collection requirements for extensions of term, drawing on the model applied in Canada." and suggested rather sternly that "Thereafter no extensions of term should be granted until data is received in a satisfactory form."

Since the present author has lobbied for the reform/abolition of s76A, the Government's response is very welcome. Hopefully repeal of the section will be swift, particularly given that better methods of accumulating useful data are available as mentioned in the Government's response.

In that regard, Benjamin Mitra-Kahn, the Chief Economist of the Australian Patent Office, recently indicated that a database linking pharmaceutical patents with PBS costs will be launched by the end of 2017. We understand that the database will be limited to connecting the IP Australia table of pharmaceutical extensions ( Open Data IPGOD) with PBS expenditure data and hence patents that have not been extended would not appear.

Swiss-style claims do not confer eligibility for a PTE: relief for the PBS

From the moment the PTE provisions were introduced into the Patents Act 1990, the Patent Office Manual of Practice and Procedure clearly indicated that Swiss-style claims did not confer eligibility for a PTE and Patent Office practice was to refuse requests for PTE if they relied only on Swiss-style claims.

However, the case law developed in such a way that it became apparent that a claim to a method of producing a product (which could involve the use of recombinant DNA technology) could render a patent eligible for a PTE – even if the patent did not include a product-by-process claim directed to the registered pharmaceutical1 and, further, even if the claim did not explicitly mention a recombinant DNA step2.

AbbVie attempted to have three patents, namely AU2012261708, AU2013203420 and AU2013257402, extended. The patents include Swiss-style claims directed to use of the antibody adalimumab (AbbVie's Humira) in the manufacture of medicaments for the treatment of ulcerative colitis, Crohn's disease and rheumatoid spondylitis, respectively. It was argued essentially that the claims relate to a method of producing the pharmaceutical that involves the use of recombinant DNA and hence they fit within the criteria for PTE.

When the Patent Office refused to allow the PTE, AbbVie appealed to the Administrative Appeals Tribunal (AAT). It was a surprise to Australian attorneys, and presumably to the Patent Office, when they were successful. Given the number of patents that would have been eligible for a PTE and the consequent long-term impact on the PBS budget, not surprisingly, the Patent Office appealed the decision of the AAT to the Federal Court.

The Federal Court Appeal was upheld and the decision handed down on 18 August 2017 (Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129). The Court found that Swiss-style claims "are not claims to pharmaceutical substances at all. [...] adalimumab is a pharmaceutical substance produced by a process that involves recombinant DNA technology. However, the claims in suit are not directed to adalimumab produced by recombinant DNA technology. They are directed to different subject matter. First, they are directed to a method or process in which adalimumab is used to produce a medicament. Secondly, they are directed to a medicament containing adalimumab that is to be used for specific therapeutic purposes [...]. These claims do not meet the requirements of [the relevant subsection of the PTE provisions]. (at 58 and 59)

The decision was anticipated given the longstanding practice of the Patent Office to refuse requests for a PTE based on such claims and the development of the precedent law surrounding PTE provisions. Nonetheless, Greg Hunt would have heaved a sigh of relief on hearing the news.

Conclusion

Granting of PTEs by the Patent Office impacts the already-stretched PBS budget. However, in rejecting the recommendation of the PC to amend the legislation to significantly reduce the number of patents that would be eligible for an extension, the Australian Government has sided with innovators ... for now. The outcome of the Government's foreshadowed consultation with the sector will not be known for some time and progress will be monitored with interest.

Meanwhile, the predictable return to "business as usual" in relation to the types of claims that confer eligibility for a PTE, while disappointing at one level, at least provides innovators with greater certainty regarding the life-expectancy of, and anticipated revenue streams from, their Australian patents.

Footnotes

1ImmunoGen Inc. [2014] APO 88 at 22-24

2 Novartis Vaccines and Diagnostics S.r.l. [2015] APO 2

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Jacinta Flattery-O'Brien
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.